Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Nature
|
October 16, 2024
Common occurrences of subsurface heatwaves and cold spells in ocean eddies
Qingyou He, Weikang Zhan, Ming Feng, et al.
Science Advances
|
February 19, 2025
Accelerated internal tides in a warming climate
Yankun Gong, Zhiwu Chen, Jiexin Xu, et al.
RSC Advances
|
May 2, 2022
Effects of mixing temperature on the extrusion rheological behaviors of rubber-based compounds
Zhongjin Du, Yu Du, Yankun Gong, et al.
Journal of Drugs in Dermatology : JDD
|
August 16, 2017
Methods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis Therapies: Implications for Interpretations of Trial Results
Richard G B Langley, Kristian Reich, Charis Papavassilis, et al.
Journal of the American Academy of Dermatology
|
May 17, 2016
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
Peter C M van de Kerkhof, Christopher E M Griffiths, Kristian Reich, et al.
Cardiology and Therapy
|
May 23, 2025
Safety and Efficacy of Tafamidis in Chinese Patients with Transthyretin Amyloid Cardiomyopathy
Zhuang Tian, Daoquan Peng, Wei Ma, et al.
American Journal of Clinical Dermatology
|
September 15, 2025
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Brett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology
|
January 23, 2024
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Brett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology
|
June 18, 2026
Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Brett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology
|
May 24, 2024
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Brett King, Jennifer Soung, Christos Tziotzios, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Nature
|
October 16, 2024
Common occurrences of subsurface heatwaves and cold spells in ocean eddies
Qingyou He, Weikang Zhan, Ming Feng, et al.
Science Advances
|
February 19, 2025
Accelerated internal tides in a warming climate
Yankun Gong, Zhiwu Chen, Jiexin Xu, et al.
RSC Advances
|
May 2, 2022
Effects of mixing temperature on the extrusion rheological behaviors of rubber-based compounds
Zhongjin Du, Yu Du, Yankun Gong, et al.
Journal of Drugs in Dermatology : JDD
|
August 16, 2017
Methods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis Therapies: Implications for Interpretations of Trial Results
Richard G B Langley, Kristian Reich, Charis Papavassilis, et al.
Journal of the American Academy of Dermatology
|
May 17, 2016
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
Peter C M van de Kerkhof, Christopher E M Griffiths, Kristian Reich, et al.
Cardiology and Therapy
|
May 23, 2025
Safety and Efficacy of Tafamidis in Chinese Patients with Transthyretin Amyloid Cardiomyopathy
Zhuang Tian, Daoquan Peng, Wei Ma, et al.
American Journal of Clinical Dermatology
|
September 15, 2025
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Brett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology
|
January 23, 2024
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Brett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology
|
June 18, 2026
Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Brett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology
|
May 24, 2024
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Brett King, Jennifer Soung, Christos Tziotzios, et al.
Page
of 2